As corticogenesis proceeds, Pax6 expression becomes more uniform across the cortex and the effects of Pax6 loss become more widespread, indicating a relationship between the levels of expression and the proliferative effect. Further evidence for a relationship between cortical Pax6 levels and progenitor proliferation comes from previous studies in which Pax6 overexpression was shown to decrease progenitor proliferation rates (Manuel et al., 2007; Georgala et al., 2011a). This effect,
as might be anticipated, is the opposite of what we observed to result from the loss of Pax6. In agreement with our model, we have shown here that Pax6 overexpression can repress Cdk6 levels. The early regional effects of Pax6 BAY 73-4506 on proliferation are important in the context of understanding how the cerebral cortex becomes divided into regions with specific cytoarchitectures and functions. The early embryonic cortex is patterned by concentration gradients of several high-level transcription factors, including
Pax6, but the mechanism by which the Pax6 gradient might contribute to the specification of cortical areas remains unclear (Bishop et al., 2000; Manuel et al., 2007). By affecting cell-cycle parameters in a region-specific manner, BMN-673 Pax6 can regulate regional differences in two critical aspects of cortical neuronal generation, namely, the numbers of neurons that are produced and their fates, both of which are likely to influence cytoarchitecture and function. There is now good evidence that cortical cell fates depend at least in part on the length of the cell cycle, in particular its G1 phase, which is a period of increased sensitivity to differentiation signals (Dehay and Kennedy, 2007; Pilaz et al., 2009). It is likely, therefore, that Pax6 can contribute to regional differences across the early developing cortex because of its graded much expression levels combined with its ability to influence directly and in a concentration-dependent manner the levels and hence the functions of cell-cycle proteins such as Cdks
and cyclins. Mice were bred in accordance with the guidelines of the UK Animals (Scientific Procedures) Act 1986. For constitutive inactivation of Pax6, we used the Pax6Sey allele (designated as Pax6− here; Hill et al., 1991). For controlled overexpression of Pax6, we used the PAX77 transgenic line ( Manuel et al., 2007). For conditional inactivation of Pax6, we used Pax6loxP ( Simpson et al., 2009), BAC transgenic strain Emx1-CreERT2 ( Kessaris et al., 2006), and R26R-YFP ( Srinivas et al., 2001) alleles. Cre expression was induced with 10 mg (at E10.5) or 12.5 mg (at E13.5) tamoxifen (orally, 50 mg ml−1; Sigma). To separate Pax6-expressing cells for gene profiling, we used the DTy54 transgene ( Tyas et al., 2006).